Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
381-400 of 1,782 trials

High-Risk Retroperitoneal Sarcoma: Chemotherapy Before Surgery

We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.

Dedifferentiated LiposarcomaLeiomyosarcoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Glioblastoma Treatment: Lomustine with or without Reirradiation

We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.

Glioblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Perianal Crohn’s Disease: FAPi-PET Imaging Study

We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.

Crohn's DiseaseFistulizing Crohn's Disease≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Brain Injury: Effects of Ketamine Treatment

We are studying whether adding ketamine to treatment helps lower the intensity of care needed for patients with acute brain injuries. We also want to see if it affects intracranial pressure.

Traumatic Brain Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Hidradenitis Suppurativa: Bimekizumab for Teens

We are studying how the drug bimekizumab works and its safety for treating moderate to severe hidradenitis suppurativa in pubertal children and adolescents.

Hidradenitis SuppurativaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyDermatology

Influenza Vaccine Study for Hematological Cancer Patients

We are testing whether a high-dose flu vaccine works better than a standard dose in patients with hematological cancers. This study aims to improve vaccine effectiveness and understand immune responses in these patients.

Hematological Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInfectious Diseases

Cancer Treatment: Immune Markers and Side Effects

We are exploring blood markers in cancer patients to identify signs of side effects from checkpoint inhibitor treatments. This research may help improve safety and management of these therapies.

Solid Tumor>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineOncology

Influenza Vaccine After Heart Attack: ELIMINATE Trial

We are studying whether an influenza vaccine can help reduce heart inflammation in people who have had a heart attack. This trial compares the vaccine to a placebo to see its effects on heart health.

Heart Attack>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCardiologyInfectious Diseases

Dapagliflozin for Patients Undergoing Heart Bypass Surgery

We are studying whether dapagliflozin can help prevent new heart rhythm problems and kidney issues in patients awaiting coronary artery bypass surgery. This research aims to improve recovery and overall outcomes after surgery.

Atrial Fibrillation and Acute Kidney Injury after CABG3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyInternal MedicineNephrology

DLBCL Treatment: Dexrazoxane for Heart Protection

We are studying whether dexrazoxane can help prevent heart problems in patients with diffuse large B-cell lymphoma receiving chemotherapy. This trial will also compare treatment responses and monitor any side effects.

Diffuse Large B-Cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyOncology

Acute Myeloid Leukemia: Cobicistat with Venetoclax and Azacitidine

We are studying a new treatment combination for patients with acute myeloid leukemia who cannot receive intensive chemotherapy. This trial aims to see if adding cobicistat to venetoclax and azacitidine improves survival and treatment outcomes.

Acute Myeloid Leukaemia3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineOncology

Metastatic Breast Cancer: Sacituzumab Govitecan Study

We are analyzing how well sacituzumab govitecan works for patients with advanced breast cancer. The study will also assess safety and explore biomarkers that may predict treatment response.

Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Sclerosis: Annual vs. Semi-Annual Ocrelizumab Infusions

We are comparing the effects of annual and semi-annual infusions of ocrelizumab in patients with active multiple sclerosis. The goal is to see which schedule better prevents disease activity over two years.

Multiple Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurology

Chronic Rhinosinusitis: Mepolizumab and Nasal Polypectomy Study

We are investigating whether combining Mepolizumab with in-office nasal polypectomy can improve quality of life for patients with chronic rhinosinusitis. The study will assess symptom relief and safety over time.

Chronic Rhinosinusitis with Nasal Polyps6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology